Trial Profile
A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary) ; Traneurocin (Primary)
- Indications COVID 2019 infections; COVID-19 respiratory infection; Ebola virus infections; Neurological disorders
- Focus Adverse reactions
- Acronyms NEUROSIVIR
- Sponsors NeuroActiva
- 23 Jul 2020 New trial record